These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 29566337)
1. Structure-Based Optimization of Small-Molecule Inhibitors for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction. Zhang M; Wang Z; Zhang Y; Guo W; Ji H J Med Chem; 2018 Apr; 61(7):2989-3007. PubMed ID: 29566337 [TBL] [Abstract][Full Text] [Related]
2. Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction. Wang Z; Zhang M; Luo W; Zhang Y; Ji H J Med Chem; 2021 May; 64(9):5886-5904. PubMed ID: 33902288 [TBL] [Abstract][Full Text] [Related]
3. Rational design of selective small-molecule inhibitors for β-catenin/B-cell lymphoma 9 protein-protein interactions. Hoggard LR; Zhang Y; Zhang M; Panic V; Wisniewski JA; Ji H J Am Chem Soc; 2015 Sep; 137(38):12249-60. PubMed ID: 26352795 [TBL] [Abstract][Full Text] [Related]
4. Discovery of 1-Benzoyl 4-Phenoxypiperidines as Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction. Li Z; Zhang M; Teuscher KB; Ji H J Med Chem; 2021 Aug; 64(15):11195-11218. PubMed ID: 34270257 [TBL] [Abstract][Full Text] [Related]
5. Discovery of Selective Small-Molecule Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety. Catrow JL; Zhang Y; Zhang M; Ji H J Med Chem; 2015 Jun; 58(11):4678-92. PubMed ID: 25985283 [TBL] [Abstract][Full Text] [Related]
6. Structure-Based Design of 1,4-Dibenzoylpiperazines as β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction Inhibitors. Wisniewski JA; Yin J; Teuscher KB; Zhang M; Ji H ACS Med Chem Lett; 2016 May; 7(5):508-13. PubMed ID: 27190602 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors. Sang P; Zhang M; Shi Y; Li C; Abdulkadir S; Li Q; Ji H; Cai J Proc Natl Acad Sci U S A; 2019 May; 116(22):10757-10762. PubMed ID: 31088961 [TBL] [Abstract][Full Text] [Related]
8. Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction. Wang Z; Zhang M; Wang J; Ji H J Med Chem; 2019 Apr; 62(7):3617-3635. PubMed ID: 30856332 [TBL] [Abstract][Full Text] [Related]
9. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling. Takada K; Zhu D; Bird GH; Sukhdeo K; Zhao JJ; Mani M; Lemieux M; Carrasco DE; Ryan J; Horst D; Fulciniti M; Munshi NC; Xu W; Kung AL; Shivdasani RA; Walensky LD; Carrasco DR Sci Transl Med; 2012 Aug; 4(148):148ra117. PubMed ID: 22914623 [TBL] [Abstract][Full Text] [Related]
10. New ZW4864 Derivatives as Small-Molecule Inhibitors for the β-Catenin/BCL9 Protein-Protein Interaction. Wang Z; Zhang M; Thompson HM; Ji H ACS Med Chem Lett; 2022 May; 13(5):865-870. PubMed ID: 35586435 [TBL] [Abstract][Full Text] [Related]
11. Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction. Wang Z; Zhang M; Quereda V; Frydman SM; Ming Q; Luca VC; Duckett DR; Ji H J Med Chem; 2021 Aug; 64(16):12109-12131. PubMed ID: 34382808 [TBL] [Abstract][Full Text] [Related]
12. Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction. Kawamoto SA; Coleska A; Ran X; Yi H; Yang CY; Wang S J Med Chem; 2012 Feb; 55(3):1137-46. PubMed ID: 22196480 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of novel 8-substituted quercetin derivatives targeting the β‑catenin/B-cell lymphoma 9 interaction. Peng X; Shen LA; Bao Y; Liu C; Chen Q; Zhang H; Li J; Zhang Q Bioorg Med Chem Lett; 2024 Jan; 98():129591. PubMed ID: 38097141 [TBL] [Abstract][Full Text] [Related]
14. AlphaScreen selectivity assay for β-catenin/B-cell lymphoma 9 inhibitors. Zhang M; Wisniewski JA; Ji H Anal Biochem; 2015 Jan; 469():43-53. PubMed ID: 25312469 [TBL] [Abstract][Full Text] [Related]
15. Recent advances in β-catenin/BCL9 protein-protein interaction inhibitors. Zhang H; Bao Y; Liu C; Li J; Zhu D; Zhang Q Future Med Chem; 2021 May; 13(10):927-940. PubMed ID: 33849283 [TBL] [Abstract][Full Text] [Related]
16. Crystal structure of a beta-catenin/BCL9/Tcf4 complex. Sampietro J; Dahlberg CL; Cho US; Hinds TR; Kimelman D; Xu W Mol Cell; 2006 Oct; 24(2):293-300. PubMed ID: 17052462 [TBL] [Abstract][Full Text] [Related]
17. Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction. Kawamoto SA; Thompson AD; Coleska A; Nikolovska-Coleska Z; Yi H; Wang S Biochemistry; 2009 Oct; 48(40):9534-41. PubMed ID: 19715304 [TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer. Zhang H; Liu C; Chen Q; Shen LA; Xiao W; Li J; Wang Y; Zhu D; Zhang Q; Li J J Med Chem; 2023 Jan; 66(2):1349-1379. PubMed ID: 36630177 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of quercetin derivatives as novel β-catenin/B-cell lymphoma 9 protein-protein interaction inhibitors. Shen LA; Peng X; Bao Y; Liu C; Zhang H; Li J; Zhu D; Zhang Q Eur J Med Chem; 2023 Feb; 247():115075. PubMed ID: 36599228 [TBL] [Abstract][Full Text] [Related]
20. SOX7 Suppresses Wnt Signaling by Disrupting β-Catenin/BCL9 Interaction. Fan R; He H; Yao W; Zhu Y; Zhou X; Gui M; Lu J; Xi H; Deng Z; Fan M DNA Cell Biol; 2018 Feb; 37(2):126-132. PubMed ID: 29271667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]